CDKN2A and glioblastoma: Another marker present in almost all samples was the deletion of chromosome 9p21 involving CDKN2A. It was present at homozygous status in the majority of patients, with some discordance between GBM and GSC, probably due to the heterogeneity of the samples, such as for GBM 56.